Seeking Alpha

Celgene Corp. (CELG +3.1%) updates guidance, saying it expects FY12 income to come in at the...

Celgene Corp. (CELG +3.1%) updates guidance, saying it expects FY12 income to come in at the higher end of previous estimates and in-line results for 2013. Net product sales are expected to double between 2013 and 2017, reaching over $12B, with numerous milestones expected in 2013 for three "potential blockbuster" drugs. One of the drugs is its existing cancer drug Abraxane, which it hopes to have approved as a treatment for pancreatic cancer - which is among the hardest to treat - sometime this year.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs